Could immunomodulation be used to prevent prion diseases?

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 3, 2012, Pages 307-317

  Wisniewski, Thomas ^a   Goi, Fernando ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF URUGUAY   (Uruguay)

Author keywords

amyloid ; chronic wasting disease; conformational disorders; Creutzfeld Jakob disease; oligomers; prion; vaccine

Indexed keywords

PRION PROTEIN; PRION PROTEIN ANTIBODY;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BOVINE SPONGIFORM ENCEPHALOPATHY; CHRONIC WASTING DISEASE; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IN VITRO STUDY; INCUBATION TIME; INFECTION PREVENTION; MUCOSAL IMMUNITY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRION DISEASE; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, MONOCLONAL; CATTLE; CLINICAL TRIALS AS TOPIC; CREUTZFELDT-JAKOB SYNDROME; DEER; ENCEPHALOPATHY, BOVINE SPONGIFORM; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOMODULATION; MICE; PRION DISEASES; PRIONS; RUMINANTS; SCRAPIE; VACCINES; WASTING DISEASE, CHRONIC;

EID: 84858223359     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.177     Document Type: Review

References (149)

1. Collee JG, Bradley R. BSE: a decade on. Lancet 349, 636-641 (1997).
2. Harman JL, Silva CJ. Bovine spongiform encephalopathy. J. Am. Vet. Med. Assoc. 234(1), 59-72 (2009).
3. Mackay GA, Knight RS, Ironside JW. The molecular epidemiology of variant CJD. Int. J. Mol. Epidemiol. Genet. 2(3), 217-227 (2011).
4. Garske T, Ghani AC. Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK. PLoS One 5(12), e15626 (2010).
5. Hilton DA, Ghani AC, Conyers L et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J. Pathol. 203(3), 733-739 (2004). (Pubitemid 38961558)
6. Hilton DA. Pathogenesis and prevalence of variant Creutzfeldt-Jakob disease. J. Pathol. 208(2), 134-141 (2006). (Pubitemid 43126107)
7. Clewley JP, Kelly CM, Andrews N et al. Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. Brit. Med. J. 338, b1442 (2009).
8. de Marco MF, Linehan J, Gill ON, Clewley JP, Brandner S. Large-scale immunohistochemical examination for lymphoreticular prion protein in tonsil specimens collected in Britain. J. Pathol. 222(4), 380-387 (2010).
9. Brown P, Brandel JP, Preese M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 67(3), 389-393 (2006). (Pubitemid 44214958)
10. Ironside JW. Variant Creutzfeldt-Jakob disease. Haemophilia 16(Suppl. 5), 175-180 (2010).
11. Brown P. Transmissible spongiform encephalopathy in the 21st century: neuroscience for the clinical neurologist. Neurology 70(9), 713-722 (2008).
12. Peden AH, Ritchie DL, Ironside JW. Risks of transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Folia Neuropathol. 43(4), 271-278 (2005). (Pubitemid 43109285)
13. Jones M, Peden AH, Yull H et al. Human platelets as a substrate source for the in vitro amplification of the abnormal prion protein (PrP) associated with variant Creutzfeldt-Jakob disease. Transfusion 49(2), 376-384 (2009).
14. Puopolo M, Ladogana A, Vetrugno V, Pocchiari M. Transmission of sporadic Creutzfeldt-Jakob disease by blood transfusion: risk factor or possible biases. Transfusion 51(7), 1556-1566 (2011).
15. Zaman SM, Hill FG, Palmer B et al. The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products. Haemophilia 17(6), 931-937 (2011).
16. Edgeworth JA, Farmer M, Sicilia A et al. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 377(9764), 487-493 (2011).
17. Peden AH, McGuire LI, Appleford NE et al. Sensitive and specific detection of sporadic Creutzfeldt-Jakob disease brain prion protein using real-time quaking induced conversion. J. Gen. Virol. doi: 10.1099/ vir.0.033365-0 (2011) (Epub ahead of print).
18. Bishop MT, Hart P, Aitchison L et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol. 5(5), 393-398 (2006).
19. Clarke P, Will RG, Ghani AC. Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK? J. R. Soc. Interface 4(15), 675-684 (2007). (Pubitemid 47204166)
20. Tranulis MA, Benestad SL, Baron T, Kretzschmar H. Atypical prion diseases in humans and animals. Top. Curr. Chem. 305, 23-50 (2011).
21. Kong Q, Zheng M, Casalone C et al. Evaluation of the human transmission risk of an atypical bovine spongiform encephalopathy prion strain. J. Virol. 82(7), 3697-3701 (2008). (Pubitemid 351429945)
22. Casalone C, Zanusso G, Acutis P et al. Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease. Proc. Natl Acad. Sci. USA 101(9), 3065-3070 (2004). (Pubitemid 38327735)
23. Biacabe AG, Jacobs JG, Bencsik A, Langeveld JP, Baron TG. H-type bovine spongiform encephalopathy: complex molecular features and similarities with human prion diseases. Prion 1(1), 61-68 (2007).
24. Comoy EE, Casalone C, Lescoutra-Etchegaray N et al. Atypical BSE (BASE) transmitted from asymptomatic aging cattle to a primate. PLoS One 3(8), e3017 (2008).
25. Beringue V, Herzog L, Reine F et al. Transmission of atypical bovine prions to mice transgenic for human prion protein. Emerg. Infect. Dis. 14(12), 1898-1901 (2008).
26. Williams ES. Chronic wasting disease. Vet. Pathol. 42(5), 530-549 (2005). (Pubitemid 41279668)
27. Aguzzi A, Sigurdson CJ. Antiprion immunotherapy: to suppress or to stimulate? Nat. Rev. Immunol. 4(9), 725-736 (2004).
28. Sigurdson CJ. A prion disease of cervids: chronic wasting disease. Vet. Res. 39(4), 41 (2008).
29. Gilch S, Chitoor N, Taguchi Y, Stuart M, Jewell JE, Schatzl HM. Chronic wasting disease. Top. Curr. Chem. 305, 51-77 (2011).
30. Williams ES, Young S. Chronic wasting disease of captive mule deer: a spongiform encephalopathy. J. Wildl. Dis. 16(1), 89-98 (1980).
31. Williams ES, Young S. Spongiform encephalopathy of Rocky Mountain elk. J. Wildl. Dis. 18(4), 465-471 (1982).
32. Beekes M, McBride PA. The spread of prions through the body in naturally acquired transmissible spongiform encephalopathies. FEBS J. 274(3), 588-605 (2007). (Pubitemid 46150854)
33. Safar JG, Lessard P, Tamguney G et al. Transmission and detection of prions in feces. J. Infect. Dis. 198(1), 81-89 (2008). (Pubitemid 351920293)
34. Belay ED, Maddox RA, Williams ES, Miller MW, Gambetti P, Schonberger LB. Chronic wasting disease and potential transmission to humans. Emerg. Infect. Dis. 10, 977-984 (2004). (Pubitemid 38697686)
35. Liberski PP, Guiroy DC, Williams ES, Walis A, Budka H. Deposition patterns of disease-associated prion protein in captive mule deer brains with chronic wasting disease. Acta Neuropathol. 102(5), 496-500 (2001). (Pubitemid 32976084)
36. Marsh RF, Kincaid AE, Bessen RA, Bartz JC. Interspecies transmission of chronic wasting disease prions to squirrel monkeys (Saimiri sciureus). J. Virol. 79(21), 13794-13796 (2005). (Pubitemid 41508190)
37. Race B, Meade-White KD, Miller MW et al. Susceptibilities of nonhuman primates to chronic wasting disease. Emerg. Infect. Dis. 15(9), 1366-1376 (2009).
38. Hamir AN, Kunkle RA, Cutlip RC et al. Experimental transmission of chronic wasting disease agent from mule deer to cattle by the intracerebral route. J. Vet. Diagn. Invest. 17(3), 276-281 (2005). (Pubitemid 40748003)
39. Hamir AN, Kunkle RA, Cutlip RC, Miller JM, Williams ES, Richt JA. Transmission of chronic wasting disease of mule deer to Suffolk sheep following intracerebral inoculation. J. Vet. Diagn. Invest. 18(6), 558-565 (2006). (Pubitemid 44770992)
40. Heisey DM, Mickelsen NA, Schneider JR et al. Chronic wasting disease (CWD) susceptibility of several North American rodents that are sympatric with cervid CWD epidemics. J. Virol. 84(1), 210-215 (2010).
41. Kurt TD, Seelig DM, Schneider JR et al. Alteration of the chronic wasting disease species barrier by in vitro prion amplification. J. Virol. 85(17), 8528-8537 (2011).
42. Hamir AN, Greenlee JJ, Nicholson EM et al. Experimental transmission of chronic wasting disease (CWD) from elk and white-tailed deer to fallow deer by intracerebral route: final report. Can. J. Vet. Res. 75(2), 152-156 (2011).
43. Krumm CE, Conner MM, Hobbs NT, Hunter DO, Miller MW. Mountain lions prey selectively on prion-infected mule deer. Biol. Lett. 6(2), 209-211 (2010).
44. Kong Q, Huang S, Zou W et al. Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models. J. Neurosci. 25(35), 7944-7949 (2005). (Pubitemid 41254397)
45. Tamguney G, Giles K, Bouzamondo-Bernstein E et al. Transmission of elk and deer prions to transgenic mice. J. Virol. 80(18), 9104-9114 (2006). (Pubitemid 44359984)
46. Sandberg M, Al-Doujaily H, Sigurdson C et al. Chronic wasting disease prions are not transmissible to transgenic mice over-expressing human prion protein. J. Gen. Virol. 91(10), 2651-2657 (2010).
47. Angers RC, Kang HE, Napier D et al. Prion strain mutation determined by prion protein conformational compatibility and primary structure. Science 328(5982), 1154-1158 (2010).
48. Collinge J. Prion strain mutation and selection. Science 328, 1111-1112 (2010).
49. Johnson CJ, Herbst A, Duque-Velasquez C et al. Prion protein polymorphisms affect chronic wasting disease progression. PLoS One 6(3), e17450 (2011).
50. Angers RC, Browning SR, Seward TS et al. Prions in skeletal muscles of deer with chronic wasting disease. Science 311(5764), 1117 (2006).
51. Mathiason CK, Powers JG, Dahmes SJ et al. Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 314(5796), 133-136 (2006). (Pubitemid 44547758)
52. Mathiason CK, Hayes-Klug J, Hays SA et al. B cells and platelets harbor prion infectivity in the blood of deer infected with chronic wasting disease. J. Virol. 84(10), 5097-5107 (2010).
53. Race B, Meade-White K, Race R, Chesebro B. Prion infectivity in fat of deer with chronic wasting disease. J. Virol. 83(18), 9608-9610 (2009).
54. Haley NJ, Seelig DM, Zabel MD, Telling GC, Hoover EA. Detection of CWD prions in urine and saliva of deer by transgenic mouse bioassay. PLoS One 4(3), e4848 (2009).
55. Tamguney G, Miller MW, Wolfe LL et al. Asymptomatic deer excrete infectious prions in faeces. Nature 461(7263), 529-532 (2009).
56. Angers RC, Seward TS, Napier D et al. Chronic wasting disease prions in elk antler velvet. Emerg. Infect. Dis. 15(5), 696-703 (2009).
57. Barria MA, Telling GC, Gambetti P, Mastrianni JA, Soto C. Generation of a new form of human PrP(Sc) in vitro by interspecies transmission from cervid prions. J. Biol. Chem. 286(9), 7490-7495 (2011).
58. Collinge J, Whitfield J, McKintosh E et al. Kuru in the 21st century -an acquired human prion disease with very long incubation periods. Lancet 367(9528), 2068-2074 (2006). (Pubitemid 43949290)
59. Smith CB, Booth CJ, Pedersen JA. Fate of prions in soil: a review. J. Environ. Qual. 40(2), 449-461 (2011).
60. Johnson CJ, Phillips KE, Schramm PT, McKenzie D, Aiken JM, Pedersen JA. Prions adhere to soil minerals and remain infectious. PLoS Pathog. 2(4), e32 (2006).
61. Saunders SE, Bartz JC, Vercauteren KC, Bartelt-Hunt SL. Enzymatic digestion of chronic wasting disease prions bound to soil. Environ. Sci. Technol. 44(11), 4129-4135 (2010).
62. Nichols TA, Pulford B, Wyckoff AC et al. Detection of protease-resistant cervid prion protein in water from a CWD-endemic area. Prion 3(3), 171-183 (2009).
63. Johnson CJ, Pedersen JA, Chappell RJ, McKenzie D, Aiken JM. Oral transmissibility of prion disease is enhanced by binding to soil particles. PLoS Pathog. 3(7), e93 (2007).
64. Abrams JY, Maddox RA, Harvey AR, Schonberger LB, Belay ED. Travel history, hunting, and venison consumption related to prion disease exposure, 2006-2007 FoodNet population survey. J. Am. Diet. Assoc. 111(6), 858-863 (2011).
65. Denkers ND, Seelig DM, Telling GC, Hoover EA. Aerosol and nasal transmission of chronic wasting disease in cervidized mice. J. Gen. Virol. 91(Pt 6), 1651-1658 (2010).
66. Haybaeck J, Heikenwalder M, Klevenz B et al. Aerosols transmit prions to immunocompetent and immunodeficient mice. PLoS Pathog. 7(1), e1001257 (2011).
67. Aguzzi A, Heikenwalder M. Prions, cytokines, and chemokines: a meeting in lymphoid organs. Immunity 22(2), 145-154 (2005). (Pubitemid 40255706)
68. Aucouturier P, Carp RI, Carnaud C, Wisniewski T. Prion diseases and the immune system. Clin. Immunol. 96, 79-85 (2000). (Pubitemid 30612774)
69. Wisniewski T, Goni F. Immunomodulation for prion and prion related diseases. Expert Rev. Vaccines 9(12), 1441-1452 (2010).
70. Bremer J, Heikenwalder M, Haybaeck J et al. Repetitive immunization enhances the susceptibility of mice to peripherally administered prions. PLoS One 4(9), e7160 (2009).
71. Brown KL, Ritchie DL, McBride PA, Bruce ME. Detection of PrP in extraneural tissues. Microscopy Res. Tech. 50(1), 40-45 (2000). (Pubitemid 30497404)
72. Mabbott NA, MacPherson GG. Prions and their lethal journey to the brain. Nat. Rev. Microbiol. 4(3), 201-211 (2006).
73. Kitamoto T, Muramoto T, Mohri S, Doh-ura K, Tateishi J. Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt-Jakob disease. J. Virol. 65(11), 6292-6295 (1991).
74. Aucouturier P, Geissmann F, Damotte D et al. Infected dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie. J. Clin. Invest. 108, 703-708 (2001). (Pubitemid 32906198)
75. Langevin C, Gousset K, Costanzo M, Richard-Le GO, Zurzolo C. Characterization of the role of dendritic cells in prion transfer to primary neurons. Biochem. J. 431(2), 189-198 (2010).
76. Sigurdsson EM, Wisniewski T. Promising developments in prion immunotherapy. Expert Rev. Vaccines 4, 607-610 (2005). (Pubitemid 41530585)
77. Goni F, Prelli F, Schreiber F et al. High titers of mucosal and systemic anti-PrP antibodies abrogates oral prion infection in mucosal vaccinated mice. Neuroscience 153, 679-686 (2008).
78. Wisniewski T, Chabalgoity JA, Goni F. Is vaccination against transmissible spongiform encephalopathies feasible? OIE Sci. Tech. Rev. 26(1), 243-251 (2007). (Pubitemid 47148825)
79. Bartz JC, DeJoia C, Tucker T, Kincaid AE, Bessen RA. Extraneural prion neuroinvasion without lymphoreticular system infection. J. Virol. 79(18), 11858-11863 (2005). (Pubitemid 41279303)
80. Bessen RA, Martinka S, Kelly J, Gonzalez D. Role of the lymphoreticular system in prion neuroinvasion from the oral and nasal mucosa. J. Virol. 83(13), 6435-6445 (2009).
81. Siso S, Gonzalez L, Jeffrey M. Neuroinvasion in Prion diseases: the roles of ascending neural infection and blood dissemination. Interdiscip. Perspect. Infect. Dis. 2010, 747892 (2010).
82. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17(9), 1060-1065 (2011).
83. Wisniewski T, Boutajangout A. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct. Funct. 214, 201-218 (2010).
84. Wisniewski T, Sigurdsson EM. Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim. Biophys. Acta Mol. Basis Dis. 1802(10), 847-859 (2010).
85. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative diseass. Annu. Rev. Neurosci. 31, 175-193 (2008).
86. Rinne JO, Brooks DJ, Rossor MN et al. (11)C-PiB PET assessment of change in fibrillar amyloid-b load in patients with Alzheimer's disease treated with bapineuzumab: a Phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9(4), 363-372 (2010).
87. Ostrowitzki S, Deptula D, Thurfjell L et al. Mechanism of amyloid removal in patients with alzheimer disease treated with gantenerumab. Arch. Neurol. doi:10.1001/ archneurol.2011.1538 (2011) (Epub ahead of print).
88. Selkoe DJ. Alzheimer's disease. Cold Spring Harb. Perspect. Biol. 3(7), pii: a004457 (2011).
89. Morgan D. Immunotherapy for Alzheimer's disease. J. Intern. Med. 269, 54-63 (2011).
90. Boutajangout A, Sigurdsson EM, Krishnamurthy PK. t as A therapeutic target for Alzheimer's disease. Curr. Alzheimer Res. 8(6), 666-677 (2011).
91. Gu J, Sigurdsson EM. Immunotherapy for tauopathies. J. Mol. Neurosci. 45(3), 690-695 (2011).
92. Come JH, Fraser PE, Lansbury PT Jr. A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc. Natl Acad. Sci. USA 90(13), 5959-5963 (1993). (Pubitemid 23191433)
93. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144 (1982). (Pubitemid 12089840)
94. Sigurdson CJ, Nilsson KP, Hornemann S et al. De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis. Proc. Natl Acad. Sci. USA 106(1), 304-309 (2009).
95. Sigurdson CJ, Nilsson KP, Hornemann S et al. A molecular switch controls interspecies prion disease transmission in mice. J. Clin. Invest. 120(7), 2590-2599 (2010).
96. Sigurdson CJ, Joshi-Barr S, Bett C et al. Spongiform encephalopathy in transgenic mice expressing a point mutation in the {b}2-{a}2 loop of the Prion protein. J. Neurosci. 31(39), 13840-13847 (2011).
97. Gabizon R, McKinley MP, Groth D, Prusiner SB. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc. Natl Acad. Sci. USA 85(18), 6617-6621 (1988).
98. Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl Acad. Sci. USA 98(16), 9295-9299 (2001). (Pubitemid 32743910)
99. Peretz D, Williamson RA, Kaneko K et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412(6848), 739-743 (2001). (Pubitemid 32771997)
100. Kim CL, Umetani A, Matsui T, Ishiguro N, Shinagawa M, Horiuchi M. Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies. Virology 320(1), 40-51 (2004). (Pubitemid 38296713)
101. Kim CL, Karino A, Ishiguro N, Shinagawa M, Sato M, Horiuchi M. Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J. Gen. Virol. 85(Pt 11), 3473-3482 (2004). (Pubitemid 39445468)
102. Pankiewicz J, Prelli F, Sy MS et al. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur. J. Neurosci. 24, 2635-2647 (2006). (Pubitemid 43801455)
103. Westergard L, Turnbaugh JA, Harris DA. A nine amino acid domain is essential for mutant prion protein toxicity. J. Neurosci. 31(39), 14005-14017 (2011).
104. Petsch B, Muller-Schiffmann A, Lehle A et al. Biological effects and use of PrPSc-and PrP-specific antibodies generated by immunization with purified full-length native mouse prions. J. Virol. 85(9), 4538-4546 (2011).
105. Sigurdsson EM, Sy MS, Li R et al. Anti-PrP antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. 336, 185-187 (2003). (Pubitemid 36044608)
106. White AR, Enever P, Tayebl M et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80-83 (2003). (Pubitemid 36323299)
107. Sadowski MJ, Pankiewicz J, Prelli F et al. Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol. Dis. 34, 267-278 (2009).
108. Song CH, Furuoka H, Kim CL et al. Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. J. Gen. Virol. 89(Pt 6), 1533-1544 (2008).
109. Solforosi L, Criado JR, McGavern DB et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303(5663), 1514-1516 (2004). (Pubitemid 38314420)
110. Lefebvre-Roque M, Kremmer E, Gilch S et al. Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice. Prion 1(3), 198-206 (2007).
111. Mallucci GR, White MD, Farmer M et al. Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 53(3), 325-335 (2007). (Pubitemid 46161264)
112. Verity NC, Mallucci GR. Rescuing neurons in prion disease. Biochem. J. 433(1), 19-29 (2011).
113. Morgan D, Diamond DM, Gottschall PE et al. Ab peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985 (2000). (Pubitemid 32101645)
114. Janus C, Pearson J, McLaurin J et al. Ab peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982 (2000). (Pubitemid 32101644)
115. Sigurdsson EM, Knudsen EL, Asuni A et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-b derivatives. J. Neurosci. 24, 6277-6282 (2004). (Pubitemid 38944217)
116. Asuni A, Boutajangout A, Scholtzova H et al. Ab derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhemorrhages in Alzheimer's model mice. Eur. J. Neurosci. 24, 2530-2542 (2006). (Pubitemid 44726765)
117. Goni F, Prelli F, Ji Y et al. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One 5(10), e13391 (2010).
118. Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid b-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6(8), 916-919 (2000). (Pubitemid 30644751)
119. Gilman S, Koller M, Black RS et al. Clinical effects of Ab immunization (AN1792) in patients with AD in an interupted trial. Neurology 64, 1553-1562 (2005). (Pubitemid 40617691)
120. Wisniewski T, Frangione B. Immunological and anti-chaperone therapeutic approaches for Alzheimer's disease. Brain Pathol. 15, 72-77 (2005). (Pubitemid 40224069)
121. Wisniewski T. Commentary on "Clinical effects of Ab immunization (AN1792) in patients with AD in an interrupted trial." Nat. Clin. Prac. Neurol. 64, 1553-1562 (2005).
122. Hock C, Konietzko U, Straffer JR et al. Antibodies against b-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554 (2003). (Pubitemid 36645030)
123. Wisniewski T, Boutajangout A. Vaccination as a therapeutic approach for Alzheimer's disease. Mount Sinai J. Med. 77, 17-31 (2010).
124. Boche D, Donald J, Love S et al. Reduction of aggregated t in neuronal processes but not in the cell bodies after Ab42 immunisation in Alzheimer's disease. Acta Neuropathol. 120, 13-20 (2010).
125. Holmes C, Boche D, Wilkinson D et al. Long-term effects of Ab42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled Phase 1 trial. Lancet 372(9634), 216-223 (2008). (Pubitemid 351978111)
126. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 6(5), 404-416 (2006).
127. Wisniewski T, Konietzko U. Amyloid-b immunization for Alzheimer's disease. Lancet Neurol. 7(9), 805-811 (2008).
128. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-b immunotherapy? Nat. Rev. Neurol. 6(2), 108-119 (2010).
129. Manuelidis L. Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent. Proc. Natl Acad. Sci. USA 95(5), 2520-2525 (1998). (Pubitemid 28145974)
130. Sigurdsson EM, Brown DR, Daniels M et al. Vaccination delays the onset of prion disease in mice. Am. J. Pathol. 161, 13-17 (2002). (Pubitemid 34760765)
131. Polymenidou M, Heppner FL, Pellicioli EC et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. Natl Acad. Sci. 101(Suppl. 2), 14670-14676 (2004). (Pubitemid 39346741)
132. Gilch S, Wopfner F, Renner-Muller I et al. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J. Biol. Chem. 278(20), 18524-18531 (2003). (Pubitemid 36799477)
133. Magri G, Clerici M, Dall'Ara P et al. Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. Vaccine 23(22), 2862-2868 (2005). (Pubitemid 40386487)
134. Schwarz A, Kratke O, Burwinkel M et al. Immunization with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci. Lett. 350, 187-189 (2003). (Pubitemid 37205197)
135. Pilon J, Loiacono C, Okeson D et al. Anti-prion activity generated by a novel vaccine formulation. Neurosci. Lett. 429(2-3), 161-164 (2007). (Pubitemid 350161127)
136. Mastroeni P, Chabalgoity JA, Dunstan SJ, Maskell DJ, Dougan G. Salmonella: immune responses and vaccines. Vet. J. 161(2), 132-164 (2001). (Pubitemid 32536811)
137. Moreno M, Kramer MG, Yim L, Chabalgoity JA. Salmonella as live trojan horse for vaccine development and cancer gene therapy. Curr. Gene Ther. 10(1), 56-76 (2010).
138. Tacket CO, Sztein MB, Wasserman SS et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect. Immun. 68(3), 1196-1201 (2000). (Pubitemid 30108510)
139. Kirkpatrick BD, McKenzie R, O'Neill JP et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 24(2), 116-123 (2006). (Pubitemid 41752998)
140. Villarreal-Ramos B, Manser J, Collins RA, Dougan G, Chatfield SN, Howard CJ. Immune responses in calves immunised orally or subcutaneously with a live Salmonella Typhimurium aro vaccine. Vaccine 16(1), 45-54 (1998). (Pubitemid 27504803)
141. Chabalgoity JA, Moreno M, Carol H, Dougan G, Hormaeche CE. A dog-adapted Salmonella Typhimurium strain as a basis for a live oral Echinococcus granulosus vaccine. Vaccine 19, 460-469 (2000).
142. Heppner FL, Christ AD, Klein MA et al. Transepithelial prion transport by M cells. Nat. Med. 7(9), 976-977 (2001).
143. Goni F, Knudsen EL, Schreiber F et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133, 413-421 (2005). (Pubitemid 40726209)
144. Wisniewski T, Mathiason C, Wong V et al. Specific anti-PrP mucosal and systemic responses in white tail deer vaccinated with attenuated Salmonella expressing deer PrP. Alz. Dementia 7(4 Suppl. 1), S687-S688 (2011).
145. Zou WQ, Cashman NR. Acidic pH and detergents enhance in vitro conversion of human brain PrPC to a PrPSc-like form. J. Biol. Chem. 277(46), 43942-43947 (2002). (Pubitemid 36157818)
146. Paramithiotis E, Pinard M, Lawton T et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med. 9(7), 893-899 (2003). (Pubitemid 36889932)
147. Hedlin PD, Cashman NR, Li L et al. Design and delivery of a cryptic PrP(C) epitope for induction of PrP(Sc)-specific antibody responses. Vaccine 28(4), 981-988 (2010).
148. Variant Creutzfeldt-Jakob disease current data (November 2011). www.cjd.ed.ac.uk/vcjdworld.htm
149. Interim data from the current national survey of abnormal prion prevalence in archived appendix specimens. www.hpa.org.uk/hpr/archives/2011/ news3611.htm#cjd